A composition for preventing the aggregation of platelets comprising, as an essential ingredient thereof, 8-bromo- or 8-chloro-3-(.beta.-diethylaminoethyl)-4-methyl-7-ethoxycarbonylmethoxycoum arin, and the use thereof.
The present invention concerns the use of cloricromene (8-chloro-3(.beta.-diethylaminoethyl)-4-methyl-7-ethoxycarbonylmethoxy coumarin) base and the salts thereof to prepare pharmaceutical compositions with cholesterol-lowering activity.
Viral and bacterial contaminants present in biological solutions are inactivated by mixing one of a novel class of photosensitizer with said solution and irradiating the mixture.
A compound having the formula: ##STR1## wherein R.sub.1 is halogen or a substituted or unsubstituted hydrocarbon group; R.sub.2 R.sub.6 and R.sub.7, which may be the same or different, each represents hydrogen or a substituted or unsubstituted hydrocarbon group, or R.sub.6 and R.sub.7 taken together may represent a hetero group having one or more hetero atoms; R.sub.3 and R.sub.4 which may be the same or different each represents a substituted or unsubstituted hydrocarbon group; or R.sub.3 and R.sub.4 taken together may represent an alkylene group or a hetero group having one or more hetero atoms and R.sub.5 is hydrogen, a substituted or unsubstituted hydrocarbon group, halogen or a free or protected hydroxy group, or a pharmaceutically acceptable salt thereof. The compounds have antiaggregating properties.
A method for photoinactivating viral and/or bacterial contaminants in blood, blood products or cell cultures is presented. The blood, blood product or cell culture is mixed with an halogenated coumarin sensitizer and irradiated with UV light to inactivate the viral and/or bacterial contaminants.
Viral and bacterial contaminants present in biological solutions are inactivated by mixing one of a novel class of photosensitizer with said solution and irradiating the mixture.
